Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,127
datasets available to search
ShareScore release 0.9.0
Dataset results
1,127 results for “cancer immunotherapy”
Supproting Materials for "Cross-Linked Selenoctanoic Acid Nanoplatform Enables Bidirectional Regulation of Intra- and Extracellular ROS: A New Avenue for Enhanced Cancer Immunotherapy" - section B
<h1><strong>Table of Content</strong></h1> <h1>1. Synthesis and characterization</h1> <h2> 1.1. SeLA</h2> <h3> 1.1.0. Lab book pages</h3> <h3> 1.1.1. NMR</h3> <h3> 1.1.2. HR-MS</h3> <h3> 1.1.3. UV</h3> <h3> 1.1.4. IR</h3> <h2> 1.2. cSeLAN</h2> <h3> 1.2.0. Lab book pages</h3> <h3> 1.2.1. NMR</h3> <h3> 1.2.2. UV</h3> <h3> 1.2.3. IR</h3> <h3> 1.2.4. GPC</h3> <h3> 1.2.5. MALDI-TOF-MS</h3> <h3> 1.2.6. DLS</h3> <h3> 1.2.7. Critical melle cncentration</h3> <h3> 1.2.8. ICP-MS</h3> <h3> 1.2.9. TEM</h3> <h2> 1.3. cLAN</h2> <h3> 1.3.0. Lab book pages</h3> <h3> 1.3.1. NMR</h3> <h3> 1.3.2. UV</h3> <h3> 1.3.3. DLS</h3> <h3> 1.3.4. GPC</h3> <h1>2. <em>In vitro</em> intra- and extracellular ROS regulation</h1> <h2> 2.0. Lab book pages</h2> <h2> 2.1. Raman scattering spectra</h2> <h2> 2.2. HPLC</h2> <h3> 2.2.1. Standard peaking</h3> <h3> 2.2.2. HPLC analysis</h3> <h2> 2.3. ICP-MS</h2> <h2> 2.4. MTT</h2> <h2> 2.5. Intracellular ROS generation</h2> <h3> 2.5.1. Fluorescence images</h3> <h3> 2.5.2. Flow fluorescence quantification</h3> <h2> 2.6. Intracellular pro-oxidation mechanism</h2> <h3> 2.6.1. Quantification of intracellular ATP</h3> <h3> 2.6.2. Quantification of intracellular NADH</h3> <h3> 2.6.3. Quantification of intracellular <strong>·</strong>OH</h3> <h3> 2.6.4. Quantification of intracellular ROS</h3> <h2> 2.7. Quantification of extracellular ROS</h2> <h1>3. <em>In vitro</em> ICD-inducing ability</h1> <h2> 3.0. Lab book pages</h2> <h2> 3.1. ATP release</h2> <h2> 3.2. HMGB1</h2> <h2> 3.3. CRT</h2> <h1>4. T cell proliferation and activation</h1> <h2> 4.0. Lab book pages</h2> <h2> 4.1. Flow cytometry analysis of the T cell proliferation</h2> <h2> 4.2. Quantification of IFN-γ secretions</h2> <h1>5. Biosafety evaluation of cSeLAN</h1> <h2> 5.0. Lab book pages</h2> <h2> 5.1. Hemolytic and hemagglutination assay</h2> <h3> 5.1.1. Hemolytic assay</h3> <h3> 5.1.2. Hemagglutination assay</h3> <h2> 5.2. Acute toxicity test</h2> <h3> 5.2.1. The amounts of dead mice</h3> <h3> 5.2.2. Body weight of mice</h3> <h3> 5.2.3. Hematological assay</h3> <h3> 5.2.4. Blood biochemistry</h3> <h3> 5.2.5. H&E staining of main organs</h3> <h1>6. Pharmacokinetic evaluation of cSeLAN</h1> <h2> 6.0. Lab book pages</h2> <h2> 6.1 Pharmacokinetic evaluation of cSeLAN</h2> <h1>7. <em>In vivo</em> anti-tumor immune response</h1> <h2> 7.0. Lab book pages</h2> <h2> 7.1. Chemiluminescence images</h2> <h3> 7.1.1. Chemiluminescence images of isoluminol</h3> <h3> 7.1.2. Chemiluminescence images of luminol</h3> <h3> 7.1.3. Related quantifications upon various treatments</h3> <h2> 7.2. Immunofluorescence images</h2> <h2> 7.3. T cell proliferation</h2> <h2> 7.4. DC proliferation</h2> <h1>8. <em>In vivo</em> anti-tumor efficacy</h1> <h2> 8.0. Lab book pages</h2> <h2> 8.1. Tumor growth</h2> <h3> 8.1.1. Tumor volume</h3> <h3> 8.1.2. Tumor weight</h3> <h3> 8.1.3. Tumor images</h3> <h2> 8.2. Body weight</h2> <h2> 8.3. Lung tissues with metastatic nodules</h2> <h3> 8.3.1. Lung tissues images</h3> <h3> 8.3.2. Number of pulmonary metastatic nodules</h3> <h3> 8.3.3. H&E</h3> <h2> 8.4. H&E of tumor and main organs</h2> <h2> 8.5. Cytokine secretions</h2> <h2> 8.6. Kaplan−Meier survival curves</h2> <h1>9. <em>In vitro</em> NK cytotoxicity and activity</h1> <h2> 9.0. Lab book pages</h2> <h2> 9.1. NK cytotoxicity</h2> <h2> 9.2. NK activity</h2>
Targeting metabotropic glutamate receptor 4 for cancer immunotherapy
<p><span><span><span><span><span><span><span><span><span><span><span>The complex mechanism regulating the immunosuppressive tumor microenvironment (TME) remains poorly understood. Here, we reported a novel role of the metabotropic glutamate receptor-4 (GRM4) in suppressing the anti-tumor immunity. We revealed in three murine syngeneic tumor models (B16, MC38, and 3LL) that either genetic knockout (<i>Grm4</i><sup>−/−</sup>) or pharmacological inhibition led to significant delay in tumor growth and synergized with immune checkpoint inhibitors in male mice. Mechanistically, perturbation of GRM4 resulted in a strong anti-tumor immunity by promoting nature killer (NK), CD4<sup>+</sup> and CD8<sup>+</sup> T cells towards an activated, proliferative, and functional phenotype. Single-cell RNA-sequencing and T Cell Receptor (TCR) profiling further defined the clonal expansion and immune landscape changes in CD8<sup>+</sup> T cells. Mechanistically, <i>Grm4</i><sup>-/- </sup>intrinsically activated IFN-g production in CD8<sup>+</sup> T cells through cAMP/CREB-mediated pathway. Our study appears to be of clinical significance as a signature of NK<sup>high</sup>-GRM4<sup>low</sup> and CD8<sup>high</sup>-GRM4<sup>low</sup> correlated with improved survival in melanoma patients. Therefore, targeting GRM4 could be exploited as a new approach for cancer immunotherapy. </span></span></span></span></span></span></span></span></span></span></span></p>
Dataset #1 related to article "NaCl enhances CD8+ T-cell effector functions in cancer immunotherapy"
<p><span>CD8<sup>+</sup> T cells control tumors but inevitably become dysfunctional. Ionic metabolism is emerging as a regulator of CD8<sup>+</sup> T cells in anti-tumor immunity. We show that sodium chloride (NaCl) counteracts T-cell dysfunction to promote cancer regression. NaCl supplementation during CD8<sup>+</sup> T-cell culture induced potent effector differentiation, IFN-</span><span>g</span><span> production and cytotoxicity while maintaining gene networks responsible for stem-like plasticity. Accordingly, adoptive transfer of tumor-specific T cells resulted in superior anti-tumor immunity in a humanized model. In mice, high-salt diet reduced growth of experimental tumors in a CD8<sup>+</sup> T cell-dependent manner, by inhibiting terminal differentiation, and by enhancing the effector potency of CD8<sup>+</sup> T cells. Mechanistically, NaCl enhanced glutamine consumption that was critical for transcriptional, epigenetic and functional reprogramming. In humans, CD8<sup>+</sup> T cells undergoing antigen recognition in tumors and predicting favorable response to checkpoint blockade immunotherapy resembled those induced by NaCl. Thus, NaCl metabolism is a major regulator of CD8<sup>+</sup> T-cell effector function, with potential translation in cancer immunotherapy.</span></p>
Video-immunotherapy: a New Approach in Breast Cancer Treatment
ClinicalTrials.gov study NCT07357207. IPD Sharing: YES. Countries: 1. Publications: 0.
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
ClinicalTrials.gov study NCT03884556. IPD Sharing: NO. Countries: 1. Publications: 0.
Physical Activity and Exercise in Cancer Immunotherapy Treatment
ClinicalTrials.gov study NCT06152926. IPD Sharing: NO. Countries: 0. Publications: 1.
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
ClinicalTrials.gov study NCT04034927. IPD Sharing: YES. Countries: 1. Publications: 0.
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
ClinicalTrials.gov study NCT02297698. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
ClinicalTrials.gov study NCT03459222. IPD Sharing: Not stated. Countries: 7. Publications: 0.
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (
ClinicalTrials.gov study NCT03709706. IPD Sharing: YES. Countries: 5. Publications: 0.
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ClinicalTrials.gov study NCT03329248. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
ClinicalTrials.gov study NCT04040231. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
ClinicalTrials.gov study NCT03555149. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
ClinicalTrials.gov study NCT07161115. IPD Sharing: YES. Countries: 1. Publications: 0.
Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes
ClinicalTrials.gov study NCT06833723. IPD Sharing: NO. Countries: 1. Publications: 0.
Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
ClinicalTrials.gov study NCT03463161. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
ClinicalTrials.gov study NCT04936230. IPD Sharing: YES. Countries: 1. Publications: 0.
Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy
ClinicalTrials.gov study NCT06461780. IPD Sharing: NO. Countries: 1. Publications: 0.
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
ClinicalTrials.gov study NCT05215470. IPD Sharing: YES. Countries: 1. Publications: 0.
Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
ClinicalTrials.gov study NCT00577356. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.